Abstract: To elucidate and compare the seroprevalence of human herpesvirus 8 (HHV8) and hepatitis C virus (HCV) among Chinese drug users, a cross-sectional study of 441 participants, was conducted in Shanghai, China, from 2012 through 2013. Seventy-seven (17.5%) participants were found to be positive for HHV8 antibodies, while 271 (61.5%) participants were positive for HCV. No significant association between HHV8 seropositivity and drug use characteristics, sexual behaviors, HCV, or syphilis was observed. In contrast, a statistically significant association between HCV seropositivity and injected drug history (OR, 2.18, 95% CI 1.41–3.37) was detected, whereas no statistically significant association between HCV seropositivity and syphilis infection (OR, 7.56, 95% CI 0.94–60.57) were observed. Pairwise comparisons showed no significant differences between latent and lytic antibodies regarding HCV and HHV8 serostatus. The study demonstrated a moderate but elevated prevalence of HHV8 infection among drug users. The discordance between HHV8 and HCV infections suggests that blood borne transmission of HHV8 might not be the predominant mode of transmission in this population, which is in contrast to HCV.
This is an open access article distributed under the
Creative Commons Attribution License which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
Export to BibTeX
MDPI and ACS Style
Zhang, T.; Liu, Y.; Zhang, Y.; Wang, J.; Minhas, V.; Wood, C.; He, N. Seroprevalence of Human Herpesvirus 8 and Hepatitis C Virus among Drug Users in Shanghai, China. Viruses 2014, 6, 2519-2530.
Zhang T, Liu Y, Zhang Y, Wang J, Minhas V, Wood C, He N. Seroprevalence of Human Herpesvirus 8 and Hepatitis C Virus among Drug Users in Shanghai, China. Viruses. 2014; 6(6):2519-2530.
Zhang, Tiejun; Liu, Ying; Zhang, Yuyan; Wang, Jun; Minhas, Veenu; Wood, Charles; He, Na. 2014. "Seroprevalence of Human Herpesvirus 8 and Hepatitis C Virus among Drug Users in Shanghai, China." Viruses 6, no. 6: 2519-2530.